News & Updates

Show Multimedia Only

First-line pembrolizumab feasible for BRAF V600–mutant melanoma

10 Nov 2022

A recent study recommends the use of pembrolizumab over BRAF/mitogen-activated protein kinase inhibitors, such as dabrafenib/trametinib, as first-line treatment in patients with advanced BRAF V600‒mutant advanced malignant melanoma.

First-line pembrolizumab feasible for BRAF V600–mutant melanoma

10 Nov 2022

AF does not reduce dapagliflozin efficacy in HF patients

10 Nov 2022 by

The presence of atrial fibrillation (AF) at baseline does not appear to modify the benefits of dapagliflozin, compared with placebo, on symptoms and clinical events in patients with heart failure and preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF), according to a study.

AF does not reduce dapagliflozin efficacy in HF patients

10 Nov 2022

Fever arises in ICU patients on dexmedetomidine

10 Nov 2022

A few patients in the intensive care unit (ICU) on dexmedetomidine therapy develop fever >38.5 °C, reveals a recent study. Higher infusion rate and longer duration of treatment are significantly associated with the fever.

Fever arises in ICU patients on dexmedetomidine

10 Nov 2022

B/F/TAF keeps HIV RNA levels suppressed at 24 months

10 Nov 2022 by

Implementing the bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) treatment regimen in routine clinical care can effectively suppress HIV in people living with HIV over 24 months of follow-up, reports a study presented at HIV Glasgow 2022.

B/F/TAF keeps HIV RNA levels suppressed at 24 months

10 Nov 2022

First ESC Guidelines on managing cardiac toxicity related to cancer treatments

09 Nov 2022 by

The inaugural European Society of Cardiology (ESC) Guideline on cardio-oncology, revealed at the ESC Congress 2022 in Barcelona, Spain, provides some much-needed information on the concurrent management of cancer and cardiovascular (CV) disease.

First ESC Guidelines on managing cardiac toxicity related to cancer treatments

09 Nov 2022

High treatment adherence cuts risks of MACE, falls after stroke

09 Nov 2022

Stroke survivors with high adherence to antihypertensive medications appear to have reduced risks of major adverse cardiovascular events (MACE) and falls requiring hospitalization, according to a study.

High treatment adherence cuts risks of MACE, falls after stroke

09 Nov 2022

Reduced tacrolimus dose needed when used with fluconazole in renal transplant patients

09 Nov 2022

Renal transplant patients need a 20-percent reduction in tacrolimus (TAC) total daily dose (TDD) when used in tandem with low-dose fluconazole (LDF) to achieve therapeutic levels, suggests a recent study.

Reduced tacrolimus dose needed when used with fluconazole in renal transplant patients

09 Nov 2022

Outpatient management, skipping redundant tests help cut cost of treating SSTIs

09 Nov 2022

Inpatient management of skin and soft tissue infections (SSTIs) often uses substantial healthcare resources, but identification of outpatient candidates and avoidance of tests with low diagnostic capacity can reduce the economic burden of SSTIs, suggests a study.

Outpatient management, skipping redundant tests help cut cost of treating SSTIs

09 Nov 2022

Cabotegravir-rilpivirine regimen feasible in hospitals

09 Nov 2022 by

A once-every-two-months (Q2M) dosing regimen of cabotegravir with rilpivirine long-acting (CAB+RPV LA) can be easily implemented in hospitals and draws high levels of acceptability, appropriateness, and feasibility feedback from healthcare staff, according to a study presented at the recently concluded 2022 HIV Glasgow Conference.

Cabotegravir-rilpivirine regimen feasible in hospitals

09 Nov 2022

TIL therapy improves PFS in patients with advanced melanoma

09 Nov 2022 by

Tumour-infiltrating lymphocyte therapy significantly improved progression-free survival (PFS) in patients with advanced melanoma compared with standard-of-care treatment with ipilimumab, according to the M14TIL trial presented at ESMO 2022.

TIL therapy improves PFS in patients with advanced melanoma

09 Nov 2022

News & Updates

Filter by Specialty:

Specialty:

First-line pembrolizumab feasible for BRAF V600–mutant melanoma

First-line pembrolizumab feasible for BRAF V600–mutant melanoma

AF does not reduce dapagliflozin efficacy in HF patients

AF does not reduce dapagliflozin efficacy in HF patients

Fever arises in ICU patients on dexmedetomidine

Fever arises in ICU patients on dexmedetomidine

B/F/TAF keeps HIV RNA levels suppressed at 24 months

B/F/TAF keeps HIV RNA levels suppressed at 24 months

First ESC Guidelines on managing cardiac toxicity related to cancer treatments

First ESC Guidelines on managing cardiac toxicity related to cancer treatments

High treatment adherence cuts risks of MACE, falls after stroke

High treatment adherence cuts risks of MACE, falls after stroke

Reduced tacrolimus dose needed when used with fluconazole in renal transplant patients

Reduced tacrolimus dose needed when used with fluconazole in renal transplant patients

Outpatient management, skipping redundant tests help cut cost of treating SSTIs

Outpatient management, skipping redundant tests help cut cost of treating SSTIs

Cabotegravir-rilpivirine regimen feasible in hospitals

Cabotegravir-rilpivirine regimen feasible in hospitals

TIL therapy improves PFS in patients with advanced melanoma

TIL therapy improves PFS in patients with advanced melanoma